Neetal Nevrekar, MD

CRS:

BJMC

Role:

Clinical

Position:

Research Clinician

Email:

drneetal24@gmail.com

Dr. Neetal Nevrekar is a research clinician at BJMC-CRS in Pune, India, where she has worked since June 2010. She is experienced in the field of clinical research on HIV, and works on various IMPAACT and ACTG Network research protocols. She worked on research protocols A5207, A5253, and A5225 as a research officer. Presently working on protocols 1077BF and 1077FF (PROMISE), A5282, A5288, and P1078 as a study clinician. 

She screens and enrolls research participants, is involved in developing the source documents for research protocols, and in completing clinical record forms. She is also responsible for adverse event reporting to RSC/DAIDS and for communications with Clinical Managing Committee (CMC) of the respective protocols eith regard to clinical management issues, toxicities, change of study drugs.

Dr. Nevrekar conducts training programs at the site for research staff, counselors and clinical personnel. She has received training in Good Clinical Practices and also completed web based GCP, HSP training. She was a member of Women’s Health Inter-network Scientific Committee (WHISC) for the IMPAACT and ACTG Network.

Dr. Nevrekar received an undergraduate degree from Grant Medical Institute, Mumbai, and a Doctor of Medicine in Obstetrics and Gynaecology from Grant Medical Institute and Bombay Hospital Research Centre. She worked as a senior medical officer at Bombay Hospital Research Centre for four years. Subsequently she was a consultant in Obstetrics and Gynaecology for six years.

  • “Vaginal delivery in a case of Pregnancy with Cervical Fibroid” - Journal of F.I.G.O, vol.49 no.2, page 77 dated April 1999.
  • “A Quadruplet Pregnancy” - Journal of F.I.G.O, vol.57 no.5, page 439-441 dated Sept-Oct. 2007.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More